Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Complement activation by recombinant adenoviruses.

G Cichon1, S Boeckh-Herwig, H H Schmidt

  • 1Institute for Biology, Department of Molecular Cell Biology, Humboldt-University Berlin at the Max Delbrueck-Center for Molecular Medicine, Berlin, Germany.

Gene Therapy
|January 23, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Repeated deep-inspiration breath-hold CT scans at planning underestimate the actual motion between breath-holds at treatment for lung cancer and lymphoma patients.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology·2023
Same author

Smaller panel, similar results: genomic profiling and molecularly informed therapy in pancreatic cancer.

ESMO open·2023
Same author

Lymphedema after pelvic and para-aortic lymphadenectomy-results of a systematic evaluation in patients with cervical and endometrial carcinoma.

Archives of gynecology and obstetrics·2022
Same author

Is de novo hepatocellular carcinoma after transjugular intrahepatic portosystemic shunt increased?

United European gastroenterology journal·2018
Same author

Local failure after radical radiotherapy of non-small cell lung cancer in relation to the planning FDG-PET/CT.

Acta oncologica (Stockholm, Sweden)·2017
Same author

Hepatobiliary and Pancreatic: Fulminant liver failure from diffuse leukemoid hepatic infiltration of melanoma.

Journal of gastroenterology and hepatology·2017
Same journal

Improving the precision of AAV lung gene therapy for SP-B deficiency using computationally derived lung-specific promoters.

Gene therapy·2026
Same journal

Recent advancements in improving cross-species applicability of bioengineered AAV capsids.

Gene therapy·2026
Same journal

Assessment of F/HN-pseudotyped lentiviral vector following intravenous delivery to mice.

Gene therapy·2026
Same journal

Applications of genome editing technologies in the treatment of human diseases.

Gene therapy·2026
Same journal

High resolution ES-DMA quantifies AAV capsid DNA content by electrical mobility to mass correlation.

Gene therapy·2026
Same journal

AAV8-mediated mouse/human PROC expression rescues thrombophilia in hereditary protein C-deficient mice.

Gene therapy·2026
See all related articles

Pre-existing anti-adenoviral antibodies in patients can activate the complement system, leading to inflammation during gene therapy. This immune response is dose-dependent and requires monitoring for systemic applications.

Area of Science:

  • Immunology
  • Gene Therapy Vectors

Background:

  • Recombinant adenoviruses are key gene therapy vectors.
  • Widespread anti-adenoviral antibodies (35-70% population) can trigger immune responses.
  • Antigen-antibody complexes activate the complement system, causing inflammation.

Purpose of the Study:

  • To determine complement system activation by adenoviruses in the presence of anti-adenoviral antibodies.
  • To quantify C3a generation in response to recombinant and wild-type adenoviruses.

Main Methods:

  • Isolated human citrate plasma challenged with adenoviruses.
  • Quantification of C3a (complement component) levels.
  • Analysis of antibody types (neutralizing vs. non-neutralizing).

Main Results:

Related Experiment Videos

  • Plasma with anti-adenoviral antibodies showed dose-dependent C3a generation.
  • High virus levels (7.5 x 10^9 particles/ml) induced significant C3a release (~3000 ng/ml).
  • Both neutralizing and non-neutralizing antibodies activated complement.

Conclusions:

  • Complement activation is significant in systemic adenoviral gene therapy.
  • Low-dose local applications may not require complement monitoring.
  • Systemic applications necessitate complement system monitoring and control strategies.